BAKER BROS. ADVISORS LP - 08 Jun 2021 Form 4 Insider Report for Aeglea BioTherapeutics, Inc. (SYRE)

Footnote F1

40,000 non-qualified stock options ("Stock Options") exercisable solely into common stock ("Common Stock") of Aeglea BioTherapeutics, Inc. (the "Issuer") were granted under the Issuer's 2016 Equity Incentive Plan to Sara Brownstein, a full-time employee of Baker Bros. Advisors LP (the "Adviser"), in her capacity as a director of the Issuer. The Stock Options have a strike price of $6.80 per share, and vest in 12 equal monthly installments beginning on July 8, 2021, or on the date of the next annual meeting of stockholders, if earlier, subject to Sara Brownstein's continued service on the Board of Directors of the Issuer (the "Board").

Footnote F2

Sara Brownstein serves on the Board as a representative of Baker Brothers Life Sciences, L.P. ("Life Sciences") and 667, L.P. ("667", and together with Life Sciences, the "Funds").

Footnote F3

Pursuant to the policies of the Adviser, Sara Brownstein does not have any right to any of the Issuer's securities issued as part of her service on the Board and the Funds are entitled to receive all of the pecuniary interest in the securities issued. The Funds each own an indirect proportionate pecuniary interest in the Stock Options. Solely as a result of Felix J. Baker's and Julian C. Baker's ownership interests in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options (i.e. no direct pecuniary interest).

Footnote F4

The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

Footnote F5

Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.